Additionally, IL‐4+Mfg‐e8+ ECVs, injected intrathecally, could prolong the IL‐4 half‐life in the brain, significantly reduced the clinical and histopathological hallmarks of experimental autoimmune encephalomyelitis (EAE) as a model of MS, and increased the cells with anti‐inflammatory markers arg1 and ym1, while decreasing the cells with the inflammatory marker iNOS. This evidence concerns the gene IL4 and myeloid sarcoma.